Nkarta, Inc.

Healthcare · Biotechnology · United States

Last price 1.56 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 111.73M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The com...